Dear Colleagues,

Glaucoma treatments include medical, surgical and laser therapies. Usually, medications represent first-line therapy even if an ocular surface disease may develop due to years of treatment, the number of eye drops, preservatives, age or previous conditions. Today, more attention is paid to the ocular surface and how quality of life could be affected by medications more than by visual field defects in the early stages of disease. Therefore, in the last few years, the literature about the study of ocular surface disease and glaucoma using new diagnostic tools has increased. Many laboratory tests have been introduced to highlight the immunological changes and inflammation in the ocular surface. Anterior segment-optical coherence tomography and in vivo confocal microscopy have been largely used to detect the early signs of ocular surface alterations and the relationship between the ocular surface and failure of filtering surgery. This is still an unsolved issue. Multidose eye drops require preservatives to prevent microbial contamination. Preservatives disrupt the ocular surface and tear film generation or increase pre-existing ocular surface disease. Recently, preservative-free eye drops, both unidose and multidose formulations, and new slow-release devices have been introduced to improve ocular surface health. Besides, laser trabeculoplasty or minimally invasive glaucoma surgery are anticipated to become more widespread in surgical treatment to replace standard anterior filtering surgery.

The purpose of this Special Issue is to illustrate the new developments that are taking place in terms of ocular surface disease diagnosis and improvements in glaucoma patients.

Dr. Michele Figus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Ocular surface
• Glaucoma
• MIGS
• Inflammation
• Tear film
• Medical treatment
• Anterior segment OCT
• On vivo confocal microscopy